PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Avelumab (MSB0010718C)
Drug: Axitinib (AG-013736)

First Posted Date: 2017-09-21

Last Posted Date: 2020-09-04

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT03289533

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
Iizuka Hospital, Iizuka, Fukuoka, Japan
🇯🇵
Kindai University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan

and more 4 locations

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: PF-06804103
Drug: PF-06804103 + Palbociclib +Letrozole

First Posted Date: 2017-09-15

Last Posted Date: 2022-03-18

Lead Sponsor: Pfizer

Target Recruit Count: 95

Registration Number: NCT03284723

Locations: 🇺🇸
UCLA Health (main campus), Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Northside Hospital, Inc. - GCS/Macon, Macon, Georgia, United States

and more 43 locations

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Phase 4

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: CP-690,500 5 mg
Drug: CP-690,550 10 mg

First Posted Date: 2017-09-13

Last Posted Date: 2023-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 140

Registration Number: NCT03281304

Locations: 🇺🇸
Clinical Applications Laboratories, Inc., San Diego, California, United States
🇺🇸
Bristol Hospital, Bristol, Connecticut, United States
🇺🇸
Connecticut Clinical Research Institute, Bristol, Connecticut, United States

and more 76 locations

A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tafamidis

First Posted Date: 2017-09-12

Last Posted Date: 2018-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03280173

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Palbociclib in Real World Practice

Completed

Conditions: Advanced Breast Cancer
Metastatic Breast Cancer

Interventions: Other: non-interventional

First Posted Date: 2017-09-12

Last Posted Date: 2023-07-24

Lead Sponsor: Pfizer

Target Recruit Count: 1285

Registration Number: NCT03280303

Locations: 🇺🇸
John Muir Clinical Research Center, Concord, California, United States
🇺🇸
Baptist Health Miami Cancer Institute, Plantation, Florida, United States
🇺🇸
Western Connecticut Health Network, Norwalk, Connecticut, United States

and more 206 locations

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Phase 1

Terminated

Conditions: Healthy
Primary Immune Thrombocytopenia
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions: Drug: PF-06755347 intravenous healthy participant
Drug: Placebo intravenous healthy participant
Drug: PF-06755347 subcutaneous healthy participant
Drug: Placebo subcutaneous healthy participant
Drug: PF-06755347 subcutaneous ITP

First Posted Date: 2017-09-08

Last Posted Date: 2024-07-05

Lead Sponsor: Pfizer

Target Recruit Count: 58

Registration Number: NCT03275740

Locations: 🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
🇪🇸
Hospital Universitario La Paz, Madrid, Spain

and more 3 locations

Immunization To Prevent Acute COPD Exacerbations

Terminated

Conditions: Pneumococcal Infections
COPD

First Posted Date: 2017-09-08

Last Posted Date: 2024-08-19

Lead Sponsor: Pfizer

Target Recruit Count: 530

Registration Number: NCT03276754

Locations: 🇪🇸
Hospital Universitario Son Espases, Palma, Islas Baleares, Spain
🇪🇸
Hospital el Bierzo, Ponferrada, León, Spain
🇪🇸
Hospital Gregorio Marañon, Madrid, Spain

and more 8 locations

A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: US-approved Neulasta
Biological: PF-06881894

First Posted Date: 2017-09-06

Last Posted Date: 2018-09-05

Lead Sponsor: Pfizer

Target Recruit Count: 422

Registration Number: NCT03273842

Locations: 🇺🇸
Seaview A Quotient Clinical Business, Miami, Florida, United States
🇺🇸
Quotient Sciences- Jacksonville, LLC, Jacksonville, Florida, United States
🇺🇸
Vince & Associates Clinical Research Inc., Overland Park, Kansas, United States

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: PF-06687234

First Posted Date: 2017-09-01

Last Posted Date: 2021-12-28

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT03269695

Locations: 🇷🇸
Clinical Hospital Center Zvezdara - Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇮🇹
ASST Rhodense - Ospedale di Circolo di Rho, Rho, Milano, Italy

and more 30 locations

Glasdegib Absolute Bioavailability Study

Phase 1

Completed

Conditions: Healthy Volunteer Study

Interventions: Drug: Glasdegib Oral Tablet
Drug: Glasdegib IV infusion

First Posted Date: 2017-09-01

Last Posted Date: 2017-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03270878

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy